Table 4

Logistic regression to determine the prognostic effects of selected variables on vision gain (gain of ≥15 letters) at (A) year 1 and (B) year 2

	Coefficient	SE	Lower 95% CI	Upper 95% CI	p Value
(A) Variables (year 1)
Country
Canada	0.61	0.82	0.05	8.44	0.72
France	0.56	0.75	0.04	7.65	0.67
Germany	0.35	0.47	0.03	4.91	0.44
Ireland	0.49	0.72	0.03	8.69	0.63
Italy	0.76	1.01	0.06	10.34	0.84
The Netherlands	0.99	1.32	0.07	13.49	0.99
UK	0.76	1.02	0.06	10.52	0.84
Reimbursement type*
Individual	1.16	0.48	0.52	2.59	0.73
National standard	0.92	0.27	0.51	1.65	0.78
Separate contract	3.32	3.09	0.54	20.55	0.20
Unknown	2.05	2.80	0.14	29.72	0.60
Other	1.16	0.48	0.52	2.59	0.73
Age at start of therapy	0.97	0.01	0.95	0.99	0.001
Baseline visual acuity score	0.95	0.00	0.94	0.96	0.000
Number of injections (ranibizumab)	1.05	0.04	0.99	1.12	0.12
Switch to other treatments	0.91	0.32	0.46	1.80	0.79
Number of ophthalmoscopies and OCT (combined)	1.03	0.02	1.00	1.07	0.05
(B) Variables (year 2)
Country
Canada	0.67	0.83	0.06	7.55	0.75
France	0.65	0.80	0.06	7.18	0.73
Germany	0.93	1.16	0.08	10.72	0.96
Ireland	0.67	0.94	0.04	10.44	0.78
Italy	0.98	1.21	0.09	11.02	0.99
The Netherlands	1.22	1.49	0.11	13.34	0.87
UK	0.82	1.01	0.07	9.22	0.87
Reimbursement type†
Individual	0.43	0.21	0.17	1.11	0.08
National standard	0.70	0.22	0.37	1.31	0.27
Unknown	0.30	0.31	0.04	2.26	0.25
Other	3.25	4.11	0.27	38.66	0.35
Age at start of therapy	0.96	0.01	0.94	0.98	0.000
Baseline visual acuity score	0.95	0.01	0.94	0.96	0.000
Number of monitoring visits	1.00	0.02	0.96	1.04	1.00
Number of injections (ranibizumab)	1.05	0.02	1.00	1.09	0.03
Number of ophthalmoscopies and OCT (combined)	1.01	0.01	0.99	1.03	0.23

*‘Patient’ category dropped and two observations not used.
†‘Separate contract’ category dropped and seven observations not used; ‘patient’ category dropped because of colinearity.
OCT, optical coherence tomography.